Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
Mariele GattoFrancesca SacconMargherita ZenFrancesca RegolaMicaela FrediLaura AndreoliAngela TincaniMaria Letizia UrbanGiacomo EmmiFulvia CeccarelliFabrizio ContiAlessandra BortoluzziMarcello GovoniChiara TaniMarta MoscaTania UbialiMaria GerosaEnrica BozzoloValentina CantiPaolo CardinalettiArmando GabrielliGiacomo TantiElisa GremeseGinevra De MarchiSalvatore De VitaSerena FasanoFrancesco CicciaGiulia PazzolaCarlo SalvaraniSimone NegriniFrancesco PuppoAndrea Di MatteoRossella De AngelisGiovanni OrsoliniMaurizio RossiniPaola FaggioliAntonella LariaMatteo PigaAlessandro MathieuSalvatore ScarpatoFrancesca W RossiAmato de PaulisEnrico BrunettaAngela CeribelliCarlo SelmiMarcella PreteVito RacanelliAngelo VaccaElena BartoloniRoberto GerliMaddalena LarosaLuca IaccarinoAndrea DoriaPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
In patients with active SLE and low damage at baseline, treatment with belimumab early in the disease may lead to favorable outcomes in a real-life setting.